Get The Alerts + Report

CG Oncology, Inc. [CGON]

Reporting date: 10/09/2025

⚠️ Neutral Insider Mix Detected

📝 What Happened

  • Insider: Mulay James
  • Role: Director
  • Company: CG Oncology, Inc. (CGON)
  • Transaction Date(s): 2025-10-09
  • Table I (Non-Derivative Securities)
    • Sale : 5,903
    • Average Sale Price: $43.99
    • Total Value: $259,672.97
    • Post-Transaction Direct Holdings: 0
    • Indirect Holdings: None reported
    • 10b5-1 Plan Used? Yes

📄 Summary

Mulay James, Director at CG Oncology, Inc. (CGON), mixed (exercised then sold) 5,903 shares on October 9, 2025, at an average price of $43.99, realizing proceeds of about ~$259,672.97. After the transaction, he now holds/retains 0 direct shares; 1,962 derivative/underlying option shares; no indirect holdings. For retail traders, this is a neutral-to-slightly bearish event: planned exercise + 10b5-1 sale — routine profit-taking under a plan.

🔑 Interpretation

  • Type: Comp-related (option exercise) with an immediate sale executed under a pre-established 10b5-1 plan.
  • Disposition: Shares were sold immediately on the same day as the acquisition (same-day sale following exercise).
  • Size Context: The sale of 5,903 shares represents the full lot acquired via the option exercise on the same day; proceeds are modest (~$260k) and this reads as routine profit-taking rather than a large-scale divestiture.
  • ATH Metric: The exercise price was $3.72 and the sale price was $43.99, a large premium to the strike — without an external live price pull, I cannot confirm exact historical all-time high/low. Relative to the exercise price and typical option exercise behavior, the sale appears opportunistic (locking in significant gain). Exact proximity to the stock's all-time high or low cannot be verified here.
  • Outlier Check: Not unusually large for a director exercising and selling a block of options; size appears typical for a single insider transaction and not an extreme outlier versus normal director-level trades.

📊 Bullish or Bearish?

Neutral

Neutral. The filing shows a same-day exercise (M) and an immediate sale (S) effected under a Rule 10b5-1 plan; net effect is reduction of direct holdings to zero but continued derivative exposure (1,962 underlying option shares). This reads as planned profit-taking rather than an unplanned negative signal; data completeness is good for this event but does not reveal cluster activity.

✅ Bottom Line (Retail Takeaway)

This transaction looks like routine profit-taking rather than a bearish signal. For retail traders, it’s noise, not a tradeable event — not worth short-/mid-term action unless corroborated by sizable coordinated sales from multiple insiders at CG Oncology (e.g., CEO, CFO, or several directors).